Physician profile
Victoria Locklear
NPI 1770949984
$1,488.08
in general payments reported to CMS, 2019-2025
11 companies · $89.36 in 2025
The $89.36 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $814 · 2022: $469 · 2023: $49.95 · 2024: $66.29 · 2025: $89.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $205.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $781.10 | 2021 | |
| Baxter Healthcare | $468.66 | 2022 | |
| Sanofi Pasteur INC. | $58.12 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $53.92 | 2023-2025 | Vaxneuvance, Gardasil 9, Rotateq |
| Seqirus USA INC | $25.30 | 2025 | Flucelvax |
| Azurity Pharmaceuticals, INC. | $21.48 | 2025 | Alvesco |
| Supernus Pharmaceuticals, INC. | $19.16 | 2024 | Qelbree |
| Pfizer INC. | $17.36 | 2021 | |
| Glaxosmithkline, LLC. | $15.36 | 2021 | |
| Neos Therapeutics, LP | $13.81 | 2023 | Cotempla Xr-Odt |
| Aytu Biopharma, INC. | $13.81 | 2024 | Karbinal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Locklear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.